Rapamicina<\/em> es un f\u00e1rmaco aprobado por la FDA que ya se ha demostrado que prolonga la vida de modelos de ratones sin progeria. Este nuevo estudio demuestra que la rapamicina reduce la cantidad de la prote\u00edna causante de la enfermedad progerina en 50%, mejora la forma anormal del n\u00facleo y extiende la vida de las c\u00e9lulas con progeria. Este estudio proporciona la primera evidencia de que la rapamicina puede ser capaz de reducir \u00a1Esto ha recibido una enorme cobertura medi\u00e1tica! Haga clic a continuaci\u00f3n para ver los enlaces a las noticias de los medios:<\/p>\n Blog de salud del Wall Street Journal<\/a><\/strong><\/p>\n Noticias de EE.UU. y reporte mundial<\/a><\/strong><\/p>\n Revista de ciencia<\/a><\/strong><\/p>\n Globo de Boston<\/a><\/strong><\/p>\n CNN<\/strong> (enlace ya no activo) La Fundaci\u00f3n para la Investigaci\u00f3n de la Progeria estuvo encantada de proporcionar c\u00e9lulas para este proyecto. Banco de c\u00e9lulas y tejidos PRF<\/a>, y ayudar a financiar la investigaci\u00f3n a trav\u00e9s de nuestro programa de subvenciones<\/a>.<\/p>\n Este nuevo y apasionante estudio demuestra el notable ritmo de la investigaci\u00f3n sobre la progeria, al tiempo que proporciona m\u00e1s conocimientos sobre el proceso de envejecimiento que nos afecta a todos.<\/p>\n *\u201dLa rapamicina revierte los fenotipos celulares y mejora la eliminaci\u00f3n de prote\u00ednas mutantes en las c\u00e9lulas de progeria de Hutchinson-Gilford\u201d [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":" [et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.6.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″ sticky_enabled=”0″] Researchers at the National Institutes of Health and Massachusetts General Hospital in Boston, MA published a new study today in Science, Translational Medicine that may lead to a new drug treatment for children with Progeria.* Rapamycin is an […]<\/p>","protected":false},"author":1,"featured_media":11636,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":" [vc_custom_heading text=\"PRF-funded study Identifies Rapamycin as Possible Treatment for Progeria\" font_container=\"tag:h1|text_align:left\" use_theme_fonts=\"yes\"]<\/p> Researchers at the National Institutes of Health and Massachusetts General Hospital in Boston, MA published a new study today in Science, Translational Medicine<\/em> that may lead to a new drug treatment for children with Progeria.*<\/p> Rapamycin<\/em> is an FDA approved drug that has previously been shown to extend the lives of non-progeria mouse models. This new study demonstrates that rapamycin decreases the amount of the disease-causing protein progerin by 50%, improves the abnormal nuclear shape, and extends the lifespan of progeria cells. This study provides the first evidence that rapamycin may be able to decrease There is tremendous media coverage on this! Click below for links to media stories:<\/p> Wall Street Journal Health Blog<\/a><\/strong><\/p> US News and World Report<\/a><\/strong><\/p> Science Magazine<\/a><\/strong><\/p> Boston Globe<\/a><\/strong><\/p> CNN<\/a> The Progeria Research Foundation was delighted to provide cells for this project from the PRF Cell & Tissue Bank<\/a>, and help fund the research through our grants program<\/a>.<\/p> This exciting new study demonstrates the remarkable pace of progeria research, while providing further insight into the aging process that affects us all.<\/p> *\"Rapamycin Reverses Cellular Phenotypes and Enhances Mutant Protein Clearance in Hutchinson-Gilford Progeria Cells\"![\"\"](\"https:\/\/web.archive.org\/web\/20170216095136im_\/https:\/\/www.progeriaresearch.org\/assets\/images\/medical_images\/Cao-with-caption.jpg\")
Efectos da\u00f1inos de la progerina en ni\u00f1os con progeria.<\/p>\n
<\/strong><\/p>\n
Kan Cao, John J. Graziotto, Cecilia D. Blair, Joseph R. Mazzulli, Michael R. Erdos, Dimitri Krainc, Francis S. Collins
29 de junio de 2011 Volumen 3 N\u00famero 89
Publicaci\u00f3n electr\u00f3nica antes de su impresi\u00f3n<\/p>\n<\/div>\nprogerin's damaging effects in children with progeria.<\/p>
<\/strong><\/p>
Kan Cao, John J. Graziotto, Cecilia D. Blair, Joseph R. Mazzulli, Michael R. Erdos, Dimitri Krainc, Francis S. Collins
29 June 2011 Vol 3 Issue 89
Epub ahead of print<\/p><\/div>","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-2054","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\n